SCHEMBL4758635

SCHEMBL4758635

CNC(=O)c1nc2ccccc2cc1-n1ccnn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.39
HCRTR1 O43613 4/20 0.39
HCRTR2 O43614 3/20 0.39
GSK3B P49841 1/20 0.38
WNT3A P56704 1/20 0.38
RAB9A P51151 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 1/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
NPC1 O15118 3/20 0.36
KDM4E B2RXH2 3/20 0.36
MITF O75030 1/20 0.36
XBP1 P17861 1/20 0.36
PAX8 Q06710 1/20 0.36
KLF5 Q13887 1/20 0.36
ALDH1A1 P00352 3/20 0.35
CASP1 P29466 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4759243 0.78 ALDH1A1 (0.45) HCRTR1HCRTR2SMN1; SMN2MAPTKDM4E
SCHEMBL17910086 0.74 NPC1 (0.47) PLK1HCRTR1HCRTR2MAPTMAPK9
SCHEMBL4758721 0.74 SMN1; SMN2 (0.39) SMN1; SMN2MAPTYTHDC1MEN1KMT2A
SCHEMBL30380622 0.71 PIK3CD (0.45) PLK1RAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3656469 0.70 ALDH1A1 (0.48) PLK1RAB9ASMN1; SMN2MAPTNPC1
SCHEMBL31556361 0.67 ALDH1A1 (0.48) HCRTR1HCRTR2SMN1; SMN2MAPTNPC1
SCHEMBL4468269 0.65 ABCG2 (0.44) HCRTR1HCRTR2SMN1; SMN2MAPTMAPK9
SCHEMBL15520031 0.65 NOTUM (0.54) PLK1RAB9ASMN1; SMN2MAPK9MAPK10
SCHEMBL4758634 0.65 HCRTR1 (0.38) HCRTR1HCRTR2SMN1; SMN2MAPTKDM4E
SCHEMBL4758636 0.65 HCRTR1 (0.38) HCRTR1HCRTR2RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188521-A1 e.g. 4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one; leukotriene biosynthesis and 5-lipoxygenase (5-LO); inhibitor; antiatherosclerotic, antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents MERCK CANADA INC. (CA) 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188521-A1 e.g. 4-(3-fluorophenyl)-7-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-2H-chromen-2-one; leukotriene biosynthesis and 5-lipoxygenase (5-LO); inhibitor; antiatherosclerotic, antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents ALOX5, ALOX15, ALOX15B PLK1 4381/4885HCRTR1 1252/4885HCRTR2 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.